Study of ALV-100 to Assess Safety, Tolerability, and PK/PD in Overweight/Obese Participants With or Without T2D

Alveus Therapeutics, Inc.

Status and phase: Enrolling; Phase 1

Conditions: Overweight or Obese, Type 2 Diabetes; Overweight or Obese Adults

Treatments: Drug: Placebo; Drug: ALV-100

Study type: Interventional

Funder types: Industry

Identifiers

NCT07399678

ALV-102-1

Details and patient eligibility

About

A Study of ALV-100 to Assess Safety, Tolerability, and PK/PD in Overweight/Obese Participants with or without Type 2 Diabetes

Enrollment: 180 estimated patients

Sex: All

Ages: 18 to 65 years old

Volunteers: No Healthy Volunteers

Inclusion criteria

For Part A and B

• Adult male and female participants, aged 18 to 65 years, inclusive, at the time of signing the informed consent form
• Body mass index between 27.0 to 39.9 kg/m2 at Screening, both inclusive; overweight should be due to excess adipose tissue, as judged by the Investigator.
• Have a stable body weight (< 5.0 kg/11 lbs self-reported change) within 90 days prior to Screening
• Females must be surgically sterile (by means of bilateral salpingectomy, hysterectomy or bilateral oophorectomy) or be post-menopausal (defined as spontaneous cessation of menses for at least 1 year prior to Screening). Females who are post-menopausal and < 55 years must have a follicle-stimulating hormone level > 40 IU/L at Screening.
• Males with female partners of child-bearing potential must be willing to practice abstinence or must agree to use condom as contraception throughout the duration of the study. This criterion may be waived for male participants who have had a documented successful vasectomy > 6 months before signing the ICF.

For Part B only

• Diagnosis of Type 2 Diabetes for at least 180 days prior to Screening.
• Glycemic control managed by diet and exercise alone or by stable treatment with metformin and/or sodium-glucose cotransporter 2 inhibitors (SGLT-2i), with no dose changes within 3 months prior to Screening.
• Hemoglobin A1c (HbA1c) between 7.0 % and 9.0% (equivalent to 53-75 mmol/mol), both inclusive, at Screening.

Exclusion criteria

For Part A and B

• History or presence of any clinically relevant respiratory, metabolic (including dyslipidemia, however mild dyslipidemia, defined as screening total cholesterol below or equal to 302 mg/dL (7.8 mmol/L) and/or screening triglyceride below 300 mg/dL (3.39 mmol/L) is accepted), renal, hepatic, gastrointestinal, endocrinological conditions (except conditions associated with type 2 diabetes in Part B) at the discretion of the Investigator.
• Participants with a family or personal history of medullary thyroid carcinoma or multiple endocrine neoplasia type 2 or a personal history of nonfamilial medullary thyroid carcinoma.
• Current or history of chronic or acute pancreatitis.
• Obesity caused by known endocrinologic disorders (e.g., Cushing syndrome) or monogenetic or syndromic forms of obesity (for example, Melanocortin 4 Receptor deficiency or Prader Willi Syndrome).
• History of major depressive disorder or other severe psychiatric disorder (for example, schizophrenia, bipolar disorder, or anxiety disorder).
• Lifetime history of a suicide attempt or of any suicidal behavior by endorsement of (answered yes to) any of the items in the suicidal behavior section on the Columbia Suicide Severity Rating Scale (C-SSRS) at Screening.
• Systolic blood pressure ≥ 140 mm Hg or diastolic blood pressure ≥ 90 mm Hg at Screening.
• History of or current cardiovascular disease, including but not limited to stable and unstable angina, myocardial infarction, congestive heart failure, transient ischemic attack, stroke, clinically significant arrhythmias and conduction disorders or venous thromboembolism.

Part A only

• History or clinical evidence of Type 1 or Type 2 diabetes mellitus, including HbA1c ≥ 6.5% and/or a fasting plasma glucose (FPG) ≥ 126 mg/dL (7.0 mmol/L) at Screening (female participants with a history of gestational diabetes are allowed).

Part B only

• Fasting plasma glucose (FPG) > 270 mg/dL (15.0 mmol/L) at Screening.
• Proliferative retinopathy or maculopathy as judged by the investigator based on a recent (within1.5 years from Screening) ophthalmologic examination.
• Severe neuropathy as judged by the investigator.
• Advanced nephropathy (defined as albuminuria ≥ 300 mg/g).
• History of severe hypoglycemia or hypoglycemic unawareness as judged by the investigator.

Trial design

Primary purpose: Treatment

Allocation: Randomized

Interventional model: Sequential Assignment

Masking: Quadruple Blind

---

180 participants in 10 patient groups, including a placebo group

Part A - Cohort 1 (ALV-100)

Experimental group

Description:

Participants with overweight or obesity without type 2 diabetes will receive ascending doses of ALV-100 by subcutaneous injection.

Treatment:

Drug: ALV-100

Part A - Cohort 1 (Placebo)

Placebo Comparator group

Description:

Participants with overweight or obesity without type 2 diabetes will receive placebo by subcutaneous injection.

Treatment:

Drug: Placebo

Part A - Cohort 2 (ALV-100)

Experimental group

Description:

Participants with overweight or obesity without type 2 diabetes will receive ascending doses of ALV-100 by subcutaneous injection.

Treatment:

Drug: ALV-100

Part A - Cohort 2 (Placebo)

Placebo Comparator group

Description:

Participants with overweight or obesity without type 2 diabetes will receive placebo by subcutaneous injection.

Treatment:

Drug: Placebo

Part A - Cohort 3 (ALV-100)

Experimental group

Description:

Participants with overweight or obesity without type 2 diabetes will receive ascending doses of ALV-100 by subcutaneous injection.

Treatment:

Drug: ALV-100

Part A - Cohort 3 (Placebo)

Placebo Comparator group

Description:

Participants with overweight or obesity without type 2 diabetes will receive placebo by subcutaneous injection.

Treatment:

Drug: Placebo

Part A - Cohort 4 (ALV-100)

Experimental group

Description:

Participants with overweight or obesity without type 2 diabetes will receive ascending doses of ALV-100 by subcutaneous injection.

Treatment:

Drug: ALV-100

Part A - Cohort 4 (Placebo)

Placebo Comparator group

Description:

Participants with overweight or obesity without type 2 diabetes will receive placebo by subcutaneous injection.

Treatment:

Drug: Placebo

Part B - T2D Cohort (ALV-100)

Experimental group

Description:

Participants with overweight or obesity with type 2 diabetes will receive ascending doses of ALV-100 by subcutaneous injection.

Treatment:

Drug: ALV-100

Part B - T2D Cohort (Placebo)

Placebo Comparator group

Description:

Participants with overweight or obesity with type 2 diabetes will receive placebo by subcutaneous injection.

Treatment:

Drug: Placebo